Literature DB >> 22419808

Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.

Xueling Wu1, Charlene Wang, Sijy O'Dell, Yuxing Li, Brandon F Keele, Zhongjia Yang, Hiromi Imamichi, Nicole Doria-Rose, James A Hoxie, Mark Connors, George M Shaw, Richard T Wyatt, John R Mascola.   

Abstract

The monoclonal antibody (MAb) VRC01 was isolated from a slowly progressing HIV-1-infected donor and was shown to neutralize diverse HIV-1 strains by binding to the conserved CD4 binding site (CD4bs) of gp120. To better understand the virologic factors associated with such antibody development, we characterized HIV-1 envelope (Env) variants from this donor and five other donors who developed broadly neutralizing antibodies. A total of 473 env sequences were obtained by single-genome amplification, and 100 representative env clones were expressed and tested for entry and neutralization sensitivity. While VRC01 neutralizes about 90% of the genetically diverse heterologous HIV-1 strains tested, only selective archival Env variants from the VRC01 donor were sensitive to VRC01 and all of the Env variants derived from the donor plasma were resistant, indicating strong antibody-based selection pressure. Despite their resistance to this broadly reactive MAb that partially mimics CD4, all Env variants required CD4 for entry. Three other CD4bs MAbs from the same donor were able to neutralize some VRC01 escape variants, suggesting that CD4bs antibodies continued to evolve in response to viral escape. We also observed a relatively high percentage of VRC01-resistant Env clones in the plasma of four of five additional broadly neutralizing donors, suggesting the presence of CD4bs-directed neutralizing antibodies in these donors. In total, these data indicate that the CD4bs-directed neutralizing antibodies exert ongoing selection pressure on the conserved CD4bs epitope of HIV-1 Env.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22419808      PMCID: PMC3347292          DOI: 10.1128/JVI.07139-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  81 in total

1.  The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.

Authors:  Rebecca M Lynch; Rong Rong; Saikat Boliar; Anurag Sethi; Bing Li; Joseph Mulenga; Susan Allen; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

2.  Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

Authors:  Penny L Moore; Elin S Gray; Daniel Sheward; Maphuti Madiga; Nthabeleng Ranchobe; Zhong Lai; William J Honnen; Molati Nonyane; Nancy Tumba; Tandile Hermanus; Sengeziwe Sibeko; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Abraham Pinter; Lynn Morris
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

3.  Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual.

Authors:  Elin S Gray; M Anthony Moody; Constantinos Kurt Wibmer; Xi Chen; Dawn Marshall; Joshua Amos; Penny L Moore; Andrew Foulger; Jae-Sung Yu; Bronwen Lambson; Salim Abdool Karim; John Whitesides; Georgia D Tomaras; Barton F Haynes; Lynn Morris; Hua-Xin Liao
Journal:  J Virol       Date:  2011-05-25       Impact factor: 5.103

4.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

5.  Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.

Authors:  Tongqing Zhou; Ivelin Georgiev; Xueling Wu; Zhi-Yong Yang; Kaifan Dai; Andrés Finzi; Young Do Kwon; Johannes F Scheid; Wei Shi; Ling Xu; Yongping Yang; Jiang Zhu; Michel C Nussenzweig; Joseph Sodroski; Lawrence Shapiro; Gary J Nabel; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

6.  The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.

Authors:  Elin S Gray; Maphuti C Madiga; Tandile Hermanus; Penny L Moore; Constantinos Kurt Wibmer; Nancy L Tumba; Lise Werner; Koleka Mlisana; Sengeziwe Sibeko; Carolyn Williamson; Salim S Abdool Karim; Lynn Morris
Journal:  J Virol       Date:  2011-03-09       Impact factor: 5.103

7.  High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men.

Authors:  Hui Li; Katharine J Bar; Shuyi Wang; Julie M Decker; Yalu Chen; Chuanxi Sun; Jesus F Salazar-Gonzalez; Maria G Salazar; Gerald H Learn; Charity J Morgan; Joseph E Schumacher; Peter Hraber; Elena E Giorgi; Tanmoy Bhattacharya; Bette T Korber; Alan S Perelson; Joseph J Eron; Myron S Cohen; Charles B Hicks; Barton F Haynes; Martin Markowitz; Brandon F Keele; Beatrice H Hahn; George M Shaw
Journal:  PLoS Pathog       Date:  2010-05-13       Impact factor: 6.823

8.  A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.

Authors:  Laura M Walker; Melissa D Simek; Frances Priddy; Johannes S Gach; Denise Wagner; Michael B Zwick; Sanjay K Phogat; Pascal Poignard; Dennis R Burton
Journal:  PLoS Pathog       Date:  2010-08-05       Impact factor: 6.823

9.  HIV-1 envelope subregion length variation during disease progression.

Authors:  Marcel E Curlin; Rafael Zioni; Stephen E Hawes; Yi Liu; Wenjie Deng; Geoffrey S Gottlieb; Tuofu Zhu; James I Mullins
Journal:  PLoS Pathog       Date:  2010-12-16       Impact factor: 6.823

10.  Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity.

Authors:  Hillel Haim; Bettina Strack; Aemro Kassa; Navid Madani; Liping Wang; Joel R Courter; Amy Princiotto; Kathleen McGee; Beatriz Pacheco; Michael S Seaman; Amos B Smith; Joseph Sodroski
Journal:  PLoS Pathog       Date:  2011-06-23       Impact factor: 6.823

View more
  59 in total

1.  Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.

Authors:  Xuejun Chen; Tongqing Zhou; Stephen D Schmidt; Hongying Duan; Cheng Cheng; Gwo-Yu Chuang; Ying Gu; Mark K Louder; Bob C Lin; Chen-Hsiang Shen; Zizhang Sheng; Michelle X Zheng; Nicole A Doria-Rose; M Gordon Joyce; Lawrence Shapiro; Ming Tian; Frederick W Alt; Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2021-01-15       Impact factor: 31.745

Review 2.  HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Authors:  Priyamvada Acharya; Sabrina Lusvarghi; Carole A Bewley; Peter D Kwong
Journal:  Expert Opin Ther Targets       Date:  2015-02-27       Impact factor: 6.902

3.  Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120.

Authors:  Anthony P West; Ron Diskin; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-27       Impact factor: 11.205

4.  Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.

Authors:  Evan M Cale; Jason Gorman; Nathan A Radakovich; Ema T Crooks; Keiko Osawa; Tommy Tong; Jiaqi Li; Raju Nagarajan; Gabriel Ozorowski; David R Ambrozak; Mangai Asokan; Robert T Bailer; Anthony K Bennici; Xuejun Chen; Nicole A Doria-Rose; Aliaksandr Druz; Yu Feng; M Gordon Joyce; Mark K Louder; Sijy O'Dell; Courtney Oliver; Marie Pancera; Mark Connors; Thomas J Hope; Thomas B Kepler; Richard T Wyatt; Andrew B Ward; Ivelin S Georgiev; Peter D Kwong; John R Mascola; James M Binley
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

5.  HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.

Authors:  Rebecca M Lynch; Patrick Wong; Lillian Tran; Sijy O'Dell; Martha C Nason; Yuxing Li; Xueling Wu; John R Mascola
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

6.  Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus.

Authors:  D Noah Sather; Sara Carbonetti; Jenny Kehayia; Zane Kraft; Iliyana Mikell; Johannes F Scheid; Florian Klein; Leonidas Stamatatos
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

Review 7.  Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.

Authors:  Weizao Chen; Tianlei Ying; Dimiter S Dimitrov
Journal:  Expert Opin Biol Ther       Date:  2013-01-07       Impact factor: 4.388

8.  HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.

Authors:  Yuxing Li; Sijy O'Dell; Richard Wilson; Xueling Wu; Stephen D Schmidt; Carl-Magnus Hogerkorp; Mark K Louder; Nancy S Longo; Christian Poulsen; Javier Guenaga; Bimal K Chakrabarti; Nicole Doria-Rose; Mario Roederer; Mark Connors; John R Mascola; Richard T Wyatt
Journal:  J Virol       Date:  2012-08-08       Impact factor: 5.103

Review 9.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

10.  An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques.

Authors:  Jennifer A Schwartz; Ilia Prado; Johnathan Misamore; Deborah Weiss; Jesse Francis; Ranajit Pal; Maria Huaman; Anthony Cristillo; George K Lewis; Robert C Gallo; Anthony L DeVico; Timothy R Fouts
Journal:  Clin Vaccine Immunol       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.